Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous TNS9.3.55-transduced CD34-positive cells

A preparation of autologous, CD34-positive hematopoietic progenitor cells (HPCs) ex vivo transduced with TNS9.3.55, a lentiviral vector encoding the human beta-globin (hemoglobin-beta, HBB) gene, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow, the deficient HBB gene is removed, and the cells are transduced with the lentiviral vector. Upon re-infusion of the TNS9.3.55-transduced CD34-positive cells back into the patient, these cells express beta-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD34-positive cells transduced with TNS9.3.55
autologous TNS9.3.55-transduced CD34+ cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search